Secretory Proteins
- 1st Edition, Volume 133 - January 17, 2023
- Editor: Rossen Donev
- Language: English
- Hardback ISBN:9 7 8 - 0 - 4 4 3 - 1 5 8 2 0 - 9
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 1 5 8 2 1 - 6
Secretory Proteins, Volume 133 in the Advances in Protein Chemistry and Structural Biology series highlights new advances in the field, including chapters on Proprotein Convertas… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteSecretory Proteins, Volume 133 in the Advances in Protein Chemistry and Structural Biology series highlights new advances in the field, including chapters on Proprotein Convertases regulate trafficking and maturation of key proteins within the secretory pathway, Secretory Proteins in Cancer Diagnosis, Senescent Cells and SASP in Cancer Microenvironment: new approaches in cancer therapy, Autophagy for secretory protein: Therapeutic targets in cancer, Secretory proteins and pathways of secretion of osteosarcoma, Monocyte secretory proteins as drug targets for arresting progression of atherosclerosis, The secretory phenotypes of envenomed cells: insights into venom cytotoxicity, Macromolecules for secretory pathway in SARS-CoV-2 infection, and much more.
Other sections cover Exploring the role of secretory proteins in the human infectious diseases diagnosis and therapeutics, Secretory proteins in orchestration of microbial pathogenesis- the curious case of Staphylococcus aureus, Influence of pathological mutations in Aspartylglucosylamine Deaspartylase causing Aspartylglucosaminuria: an in silico approach, and Change in conformational dynamics of Lipase A secretory protein upon mutation causing Wolman disease.
- Provides the authority and expertise of leading contributors from an international board of authors
- Presents the latest release in the Advances in Protein Chemistry and Structural Biology series
- Updated release includes the latest information on the Secretory Proteins
Researchers and students
- Cover
- Title page
- Table of Contents
- Copyright
- Contributors
- Chapter One: Proprotein convertases regulate trafficking and maturation of key proteins within the secretory pathway
- Abstract
- 1: Introduction
- 2: Basic PCs
- 3: SKI-1/S1P
- 4: PCSK9
- 5: Conclusions
- Acknowledgments
- References
- Chapter Two: Exploring the macromolecules for secretory pathway in cancer disease
- Abstract
- 1: Introduction
- 2: Secretory proteins
- 3: The cancer secretome
- 4: Methods for analyzing secretory proteins
- 5: Tumor cell secretome
- 6: Effect of therapy-induced tumor secretome on tumor microenvironment
- 7: Cancer secretome from heterotypic cells
- 8: The angiogenesis-derived secretome
- 9: Conclusion
- Acknowledgment
- References
- Chapter Three: Current and emerging biomarkers in ovarian cancer diagnosis; CA125 and beyond
- Abstract
- 1: Introduction
- 2: Ovarian cancer and its pathogenesis
- 3: Challenges/limitations associated with OC diagnosis
- 4: Molecular diagnosis of OC
- 5: Recent advances in OC diagnosis
- 6: Conclusion and future directions
- References
- Chapter Four: Senescent cells and SASP in cancer microenvironment: New approaches in cancer therapy
- Abstract
- 1: Introduction
- 2: Morphological and functional characteristics of senescent cells
- 3: Metabolism of senescent cell
- 4: The senescence-associated secretory phenotype
- 5: Pharmacological targeting of senescent cells in cancer therapy: Senolytics and senomorphics
- 6: Reversal of senescence
- 7: Conclusion
- Acknowledgments
- References
- Chapter Five: Autophagy for secretory protein: Therapeutic targets in cancer
- Abstract
- 1: Introduction
- 2: Conventional and unconventional protein secretion
- 3: Role of autophagy in conventional protein secretion
- 4: Role of autophagy in unconventional protein secretion
- 5: Crosstalk between secretory and degradative autophagy
- 6: Autophagy-modulated protein secretion in cancer
- 7: Conclusion
- References
- Chapter Six: The role of SPARC/ON in human osteosarcoma
- Abstract
- 1: Introduction
- 2: Materials and methods
- 3: Conclusions
- Conflicts of interest
- References
- Chapter Seven: The secretory phenotypes of envenomed cells: Insights into venom cytotoxicity
- Abstract
- 1: Introduction
- 2: Venom toxins with reported cytotoxicity
- 3: Molecular mechanism of venom toxins’ cytotoxicity
- 4: Antivenom and dermonecrosis
- 5: Secretome analysis of cytotoxicity: Phenotypic changes in envenomed cells and tissues
- 6: Conclusion
- References
- Chapter Eight: Exploring the role of secretory proteins in the human infectious diseases diagnosis and therapeutics
- Abstract
- 1: Introduction
- 2: Malaria
- 3: HIV
- 4: Tuberculosis
- 5: Leishmaniasis
- 6: COVID-19
- 7: Conclusion
- References
- Chapter Nine: Secretory proteins in the orchestration of microbial virulence: The curious case of Staphylococcus aureus
- Abstract
- 1: Introduction
- 2: Exoenzymes as virulence factors
- 3: Exotoxins as virulence factors
- 4: Complement evading proteins
- 5: Host protein modulators
- 6: Conclusion
- References
- Chapter Ten: Structure-based virtual screening to identify potential lipase inhibitors to reduce lipid storage in Wolman disorder
- Abstract
- 1: Introduction
- 2: Materials and methods
- 3: Results and discussion
- 4: Conclusion
- References
- Further reading
- No. of pages: 376
- Language: English
- Edition: 1
- Volume: 133
- Published: January 17, 2023
- Imprint: Academic Press
- Hardback ISBN: 9780443158209
- eBook ISBN: 9780443158216
RD
Rossen Donev
Rossen Donev received his PhD degree in 1999 from the Institute of Molecular Biology, Bulgarian Academy of Sciences. He did postdoctoral training at Imperial Cancer Research Fund, UK (renamed after the merger with Cancer Research Campaign to Cancer Research UK, London Research Institute) and Cardiff University. In 2007 he was awarded a New Investigator Grant Award from the Medical Research Council (UK) to establish himself as an independent Principle Investigator. In 2010 Dr. Donev was appointed Senior Lecturer at Swansea University. In 2016 Dr. Donev joined MicroPharm Ltd (UK) where currently he is Head of Research. He has published more than 60 research papers, chaired scientific meetings and given invited plenary talks. Rossen Donev has consulted on projects related to development of treatments for neurodevelopmental disorders and cancer therapies. He serves as Editor-in-Chief of the Advances in Protein Chemistry and Structural Biology and on editorial board of several other journals. His research interests include signaling pathways involved in neuropsychiatric disorders and tumor escape from the immune system, and development of therapeutic strategies for their treatment. More recently he has focused on development of immunotherapeutics for non-systemic applications.
Affiliations and expertise
Head of Research, MicroPharm Limited, UKRead Secretory Proteins on ScienceDirect